Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Mohs’ micrographic surgery for high-risk skin tumours
Tom Lucke
The goal of surgery in the management of any form of skin cancer is to completely remove the tumour. For the most common form of skin cancer – that is, basal cell carcinoma (BCC) – this is generally achieved by excising the tumour with a 3–4 mm margin of normal surrounding skin. Cure rates of about 90% can be achieved with this technique when treating well-defined, low-risk BCCs – such as nodular BCCs.
Dermatology in practice
2008;
16
(3): 16–18
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
Gilead and LEO announce $1.7bn inflammation deal
Regeneron’s Libtayo shows promise in phase 3 high-risk skin cancer trial
Bristol Myers Squibb shares promising phase 3 results for Sotyktu in psoriatic arthritis
FDA grants approval to Organon’s Vtama cream in atopic dermatitis
EMA committee recommends Galderma’s nemolizumab for prurigo nodularis and atopic dermatitis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy